ESMO Abstract
Category: dates
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
Title SITC
TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma
J. Foloppe, et al. Frontiers in Microbiology Septembre 2025 – Download the Article
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data – Randomization to be Completed in Phase II Part in Q4 2025
H1 financial resultats
A Pseudocowpox virus vector to generate human B cell-based vaccines
C. Thioudellet, et al. CICON 2025 – Download the Poster
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
ESMO 2025
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independant Director
Nomination E Quiles
Utilisation de l’analyseur xCELLigence RTCA eSight pour l’évaluation de la nouvelle plateforme de virus oncolytique de Transgene
B. Moreau et al.AFH 2025Download the poster herePoster presentation
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
TG4050
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
investor meetings